In the top M&A, NYSE-listed CDMO Catalent entered into a merger agreement with life sciences investor Novo Holdings, under which the latter will acquire Catalent in an all-cash transaction that values Catalent at $16.5bn on an enterprise value basis. Catalent is focused on delivery technologies and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. Post-merger, Catalent’s shares will no longer trade on the NYSE and will become a private company. Financing reached $9.3bn in biopharma, $836.2m in device, and $488.8m in diagnostics.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?